Pharmaceutical landscape for Kratom Alkaloids
Landscape analysis Two structural facts define the field. First, the highest-value IP is not raw-plant IP; it sits on new chemical entities, isotopologues, salts/polymorphs, and delivery systems. That is why the strongest granted U.S. positions cluster around mitragynine-class opioid receptor modulators and C11-modified analogs, while 3-deuteromitragynine and its salt forms are protected in later continuation-style filings. The claims are usually framed around pain, mood/anxiety disorders, opioid-use / withdrawal indications, or, more selectively, alcohol use disorder. Second, a broad composition family filed by Caamtech functions almost like a catch-all purified-alkaloid platform. It expressly lists many kratom constituents, including mitragynine, 7-hydroxymitragynine, paynantheine, speciociliatine, speciogynine, mitraphylline, and others, but the family is broad and combinatorial rather than a marker that each listed alkaloid has its own dedicated drug-development program. The original U.S. case was abandoned, while a later continuation remained pending in the retrieved record. Within the papers, the most actionable non-mitragynine signals are narrower. Speciociliatine is being revisited as a meaningful μ-opioid partial agonist and circulating metabolite; paynantheine and speciogynine stand out for serotonergic activity and as scaffolds for δ-opioid-leaning alcohol-use-disorder derivatives; mitraphylline is present in kratom chemistry and ADME studies but does not, in the retrieved English primary sources, anchor a comparably mature therapeutic IP track. Alkaloid and derivative table Rows are ordered from the strongest compound-specific IP programs to broader or earlier-stage research coverage. Where the retrieved source did not expose a date or definitive national-phase status, it is marked unspecified. Dedicated programs and derivative classes Alkaloid / derivative Claimant(s) Patent or application numbers, jurisdiction, status, dates Intended use / indication Development stage Key claims or mechanism from patent / paper Primary sources Mitragynine; also MG, (-)-mitragynine; C23H30N2O4; structure in PubChem CID 3034396 Kures; Syncotrance; University of Florida group / UFRF; NIDA clinical program WO2022234524A1 (PCT, ceased; priority 2021-05-06, filed 2022-05-06, pub 2022-11-10) plus named national phases incl. US20240239798A1, GB2623043A, EP4351573A1; US20230364172A1 (US, abandoned; priority 2022-05-14, filed 2023-05-15, pub 2023-11-16) with continuation US20240366702A1 (pending, filed 2024-03-18, publication date unspecified in retrieved source); WO2024092269A1 (WIPO, published; priority 2022-10-28, pub 2024-05-02); NCT07204171 (ClinicalTrials.gov, Phase 1 oral MG001; sponsor NIDA). Formulation / CMC, improved oral bioavailability, palatability, solubility, and controlled oral delivery; clinical safety/PK for purified mitragynine formulation. Clinical Phase 1 for MG001; otherwise formulation / preclinical. Patents emphasize salts/crystalline forms of mitragynine and phospholipid or oral-bioavailability formulations. Papers characterize mitragynine as a low-efficacy / partial MOR agonist and atypical opioid scaffold rather than a conventional opioid full agonist. PubChem structure; salts/polymorphs family; Syncotrance formulation; UF formulation; ClinicalTrials.gov study. 7-Hydroxymitragynine; also 7-HMG, 7-OH, 7-OH-MIT; C23H30N2O5; structure in PubChem Individual inventors; early Chinese academic synthesis filing; also listed in broad composition family CN106967067A (China, pending; priority/filed 2017-05-25, pub 2017-07-21); US12492201B1 (US, active/granted; priority 2024-05-15, filed 2025-02-13, pub/grant 2025-12-09; priority claimed from US12466830B1 path). Primarily manufacturing / purification IP; research papers tie the compound to analgesia / pain signaling as mitragynine’s active metabolite. Preclinical / unknown as a therapeutic development program in retrieved primary sources. Patent claims cover conversion of mitragynine to high-purity 7-OH via routes including PIFA oxidation, Fenton chemistry, CYP450-mediated conversion, or enzyme/light-assisted conversion. The 2019 ACS Central Science paper identifies 7-OH as an active metabolite of mitragynine and a key mediator of its analgesic effect via μ-opioid receptor signaling. PubChem; CN106967067A; US12492201B1; ACS Cent. Sci. 2019. Mitragynine pseudoindoxyl; also MP; C23H30N2O5; structure in PubChem Memorial Sloan Kettering family; later Columbia / MSK / RFMH C11 family Core early family WO2016176657A1 (PCT, ceased; priority 2015-04-30, filed 2016-04-29, pub 2016-11-03); granted national phases listed as US11046692B2, EP3291676B1, CA2983314C; later continuation US20220024923A1 (filed 2021-06-24, pending in retrieved family listing). Analgesia / pain; scaffold optimization for atypical opioid activity. Preclinical. The associated paper reports that conversion from the indole to spiro-pseudoindoxyl form markedly increases opioid-receptor affinity; the pseudoindoxyls showed promise as potent analgesics with MOR agonism / DOR antagonism. Later analog IP also claims C11-substituted pseudoindoxyls. PubChem; WO2016176657A1 family; J. Med. Chem. 2016. 3-Deuteromitragynine; also 3-DM; deuterated mitragynine analog; structure in patent figures Columbia / RFMH / Memorial Sloan Kettering; Kures WO2020160280A1 (PCT, ceased; priority 2019-02-01, filed 2020-01-30, pub 2020-08-06); country-status lines in the retrieved family page show US17/427,502 pending, CA3128726A pending, CN202080024396.7A pending, JP2021544618A pending, EP withdrawn, AU abandoned, KR ceased; follow-on WO2022234524A1 (PCT, ceased; priority 2021-05-06, filed 2022-05-06, pub 2022-11-10) claims salts and polymorphs of mitragynine and 3-DM. Patents state pain, depressive / anxiety / mood disorders, substance-use disorders, opioid use disorder / withdrawal, alcohol use disorder, and physicochemical / purification improvements. Preclinical. The deuterated family claims that deuteration attenuates formation of toxic 3-dehydromitragynine (DHM) while preserving formation of the active 7-OH metabolite; the later Kures family adds salt / crystalline-form claims for manufacturability and properties. WO2020160280A1 family; WO2022234524A1 family. C11-substituted mitragynine-family analogs; includes C11-modified analogs of mitragynine, 7-hydroxymitragynine, mitragynine-ethylene glycol adduct, and mitragynine pseudoindoxyl Columbia / RFMH / Memorial Sloan Kettering WO2020037136A1 (PCT, ceased; priority 2018-08-16, filed 2019-08-15); US11760758B2 (US, active/granted; filed 2021-02-16, grant/pub 2023-09-19); EP3836924A1 (EP, withdrawn in retrieved family record). Pain, mood disorders, substance use disorders, including claims mentioning opioid addiction / withdrawal symptoms. Preclinical. The family claims that C11 substitution unexpectedly tunes opioid-receptor efficacy across MG, 7-OH, MG-EG, and pseudoindoxyl scaffolds, giving medicinal chemists a way to fine-tune receptor signaling rather than simply increase potency. US11760758B2 / WO2020037136A1; site-selective C–H functionalization paper. Mitragynine-class opioid receptor modulators; broader Columbia family covering mitragynine-alkaloid-derived modulators, including deuterium-enriched embodiments Columbia WO2017165738A1 (PCT, ceased; priority 2016-03-25, filed 2017-03-24, pub 2017-09-28); search-result family lines show US10961244B2 (granted 2021-03-30) and US11912707B2 (granted 2024-02-27). Pain, depressive disorder, mood disorder, anxiety disorder; combination claims with NMDAR antagonists, NK antagonists, and DOR agonists. Preclinical. The patent family positions the mitragynine scaffold as a source of opioid receptor modulators with psychiatric and analgesic claims, and it explicitly mentions deuterium-enriched embodiments. Analytically, this family looks like a foundational bridge between the earlier analog work and the later C11/deuterated branches. WO2017165738A1; grant listings; 2016 receptor-signaling / scaffold paper. Natural minor alkaloids and focused derivative leads Alkaloid / derivative Claimant(s) Patent or application numbers, jurisdiction, status, dates Intended use / indication Development stage
